The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival

Brain Research

Volumn 1249, Issue , 2009, Pages 244-250

  Lee, Hyoung gon ^a   Zhu, Xiongwei ^a   Casadesus, Gemma ^b   Pallàs, Mercé ^c   Camins, Antoni ^c   O'Neill, Michael J ^d   Nakanishi, Shigetada ^e   Perry, George ^a,f   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e OSAKA BIOSCIENCE INSTITUTE   (Japan)

^f University of San Antonio   (United States)

Author keywords

ERK; mGluR2; Neuroprotection

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL DEATH; CELL SURVIVAL; CYTOTOXICITY; ENZYME ACTIVATION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO CULTURE; NERVE CELL; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; MAP KINASE SIGNALING SYSTEM; NEUROBLASTOMA; NEURONS; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; TAU PROTEINS; TRANSFECTION;

EID: 58049191297     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.10.055     Document Type: Article

References (42)

1. Allen J.W., Ivanova S.A., Fan L., Espey M.G., Basile A.S., and Faden A.I. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J. Pharmacol. Exp. Ther. 290 (1999) 112-120
2. Baraban J.M., Fiore R.S., Sanghera J.S., Paddon H.B., and Pelech S.L. Identification of p42 mitogen-activated protein kinase as a tyrosine kinase substrate activated by maximal electroconvulsive shock in hippocampus. J. Neurochem. 60 (1993) 330-336
3. Bond A., Jones N.M., Hicks C.A., Whiffin G.M., Ward M.A., O'Neill M.F., Kingston A.E., Monn J.A., Ornstein P.L., Schoepp D.D., Lodge D., and O'Neill M.J. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther. 294 (2000) 800-809
4. Bruno V., Battaglia G., Copani A., D'Onofrio M., Di Iorio P., De Blasi A., Melchiorri D., Flor P.J., and Nicoletti F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 21 (2001) 1013-1033
5. Buisson A., and Choi D.W. The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology 34 (1995) 1081-1087
6. Buisson A., Yu S.P., and Choi D.W. DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons. Eur. J. Neurosci. 8 (1996) 138-143
7. Cash A.D., Aliev G., Siedlak S.L., Nunomura A., Fujioka H., Zhu X., Raina A.K., Vinters H.V., Tabaton M., Johnson A.B., Paula-Barbosa M., Avila J., Jones P.K., Castellani R.J., Smith M.A., and Perry G. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am. J. Pathol. 162 (2003) 1623-1627
8. Chiamulera C., Albertini P., Valerio E., and Reggiani A. Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur. J. Pharmacol. 216 (1992) 335-336
9. Copani A., Bruno V., Battaglia G., Leanza G., Pellitteri R., Russo A., Stanzani S., and Nicoletti F. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol. Pharmacol. 47 (1995) 890-897
10. Desdouits-Magnen J., Desdouits F., Takeda S., Syu L.J., Saltiel A.R., Buxbaum J.D., Czernik A.J., Nairn A.C., and Greengard P. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J. Neurochem. 70 (1998) 524-530
11. Ferraguti F., Baldani-Guerra B., Corsi M., Nakanishi S., and Corti C. Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur. J. Neurosci. 11 (1999) 2073-2082
12. Gardner A.M., and Johnson G.L. Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J. Biol. Chem. 271 (1996) 14560-14566
13. Gass P., Kiessling M., and Bading H. Regionally selective stimulation of mitogen activated protein (MAP) kinase tyrosine phosphorylation after generalized seizures in the rat brain. Neurosci. Lett. 162 (1993) 39-42
14. Hirano A., and Iida M. Topographic study of Alzheimer's neurofibrillary changes: a personal perspective. J. Alzheimers Dis. 9 (2006) 53-60
15. Iqbal K., and Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J. Alzheimers Dis. 9 (2006) 219-242
16. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., and Schoepp D.D. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur. J. Pharmacol. 377 (1999) 155-165
17. Kril J.J., Patel S., Harding A.J., and Halliday G.M. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol. (Berl) 103 (2002) 370-376
18. Kulich S.M., and Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 77 (2001) 1058-1066
19. Kyoung Pyo H., Lovati E., Pasinetti G.M., and Ksiezak-Reding H. Phosphorylation of tau at THR212 and SER214 in human neuronal and glial cultures: the role of AKT. Neuroscience 127 (2004) 649-658
20. Lee H.G., Ogawa O., Zhu X., O'Neill M.J., Petersen R.B., Castellani R.J., Ghanbari H., Perry G., and Smith M.A. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol. (Berl) 107 (2004) 365-371
21. Lee H.G., Zhu X., O'Neill M.J., Webber K., Casadesus G., Marlatt M., Raina A.K., Perry G., and Smith M.A. The role of metabotropic glutamate receptors in Alzheimer's disease. Acta Neurobiol. Exp. (Wars) 64 (2004) 89-98
22. Lee H.G., Perry G., Moreira P.I., Garrett M.R., Liu Q., Zhu X., Takeda A., Nunomura A., and Smith M.A. Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends Mol. Med. 11 (2005) 164-169
23. Li H.L., Wang H.H., Liu S.J., Deng Y.Q., Zhang Y.J., Tian Q., Wang X.C., Chen X.Q., Yang Y., Zhang J.Y., Wang Q., Xu H., Liao F.F., and Wang J.Z. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3591-3596
24. Matarredona E.R., Santiago M., Venero J.L., Cano J., and Machado A. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J. Neurochem. 76 (2001) 351-360
25. Miyamoto M., Ishida M., and Shinozaki H. Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group II metabotropic glutamate receptors against intraventricular kainate in the rat. Neuroscience 77 (1997) 131-140
26. Morsch R., Simon W., and Coleman P.D. Neurons may live for decades with neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58 (1999) 188-197
27. Nair V.D., Niznik H.B., and Mishra R.K. Interaction of NMDA and dopamine D2L receptors in human neuroblastoma SH-SY5Y cells. J. Neurochem. 66 (1996) 2390-2393
28. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
29. Otani S., Auclair N., Desce J.M., Roisin M.P., and Crepel F. Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases. J. Neurosci. 19 (1999) 9788-9802
30. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A.L., Zhu X., Raina A.K., Holbrook N., Siedlak S.L., Harris P.L., and Smith M.A. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10 (1999) 2411-2415
31. Phillips T., Barnes A., Scott S., Emson P., and Rees S. Human metabotropic glutamate receptor 2 couples to the MAP kinase cascade in Chinese hamster ovary cells. Neuroreport 9 (1998) 2335-2339
32. Reid S.N., and Romano C. Developmental and sensory-dependent changes of group II metabotropic glutamate receptors. J. Comp. Neurol. 429 (2001) 270-276
33. Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., and Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J. Neurochem. 74 (2000) 1587-1595
34. Romano C., Yang W.L., and O'Malley K.L. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. 271 (1996) 28612-28616
35. Smith M.A. Alzheimer disease. Int. Rev. Neurobiol. 42 (1998) 1-54
36. Smith M.A., Casadesus G., Joseph J.A., and Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33 (2002) 1194-1199
37. Tanabe Y., Masu M., Ishii T., Shigemoto R., and Nakanishi S. A family of metabotropic glutamate receptors. Neuron. 8 (1992) 169-179
38. Webber K.M., Smith M.A., Lee H.G., Harris P.L., Moreira P., Perry G., and Zhu X. Mitogen- and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer's disease. J. Neurosci. Res. 79 (2005) 554-560
39. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
40. Zhu X., Castellani R.J., Takeda A., Nunomura A., Atwood C.S., Perry G., and Smith M.A. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Dev. 123 (2001) 39-46
41. Zhu X., Lee H.G., Raina A.K., Perry G., and Smith M.A. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11 (2002) 270-281
42. Zhu X., Sun Z., Lee H.G., Siedlak S.L., Perry G., and Smith M.A. Distribution, levels, and activation of MEK1 in Alzheimer's disease. J Neurochem 86 (2003) 136-142